去年，碧迪医疗表现最佳的业务板块Medication Delivery Solutions实现营收4.58B美元。United States的营收贡献最高，去年达到12.79B美元。最近一个季度，截至2026-06-30，碧迪医疗表现最佳的业务板块Medication Delivery Solutions实现营收1.16B美元。United States的营收贡献最高，达到3.08B美元。

业务

营业收入

占比

年报

年报

单季报

Medication Delivery Solutions

Medication Management Solutions

Pharmaceutical Systems

Peripheral Intervention

Specimen Management

Integrated Diagnostic Solutions

Urology and Critical Care

Surgery

Biosciences

Advanced Patient Monitoring

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

Medication Delivery Solutions

4.58B(20.95%)

4.43B(21.88%)

4.29B(22.16%)

4.31B(22.83%)

4.10B(21.44%)

3.60B(22.37%)

Medication Management Solutions

3.47B(15.91%)

3.30B(16.29%)

2.98B(15.38%)

2.53B(13.42%)

2.43B(12.71%)

2.45B(15.27%)

Pharmaceutical Systems

2.32B(10.64%)

2.27B(11.23%)

2.23B(11.51%)

2.00B(10.60%)

1.83B(9.56%)

1.59B(9.87%)

Peripheral Intervention

2.00B(9.14%)

1.93B(9.55%)

1.86B(9.63%)

1.76B(9.32%)

1.71B(8.94%)

1.51B(9.40%)

Specimen Management

1.87B(8.57%)

--(--)

Integrated Diagnostic Solutions

1.84B(8.42%)

3.68B(18.17%)

3.62B(18.71%)

4.18B(22.18%)

5.22B(27.31%)

3.53B(21.97%)

Urology and Critical Care

1.65B(7.55%)

1.55B(7.68%)

1.37B(7.09%)

1.30B(6.92%)

1.23B(6.44%)

1.13B(7.03%)

Surgery

1.57B(7.20%)

1.49B(7.37%)

1.50B(7.73%)

1.40B(7.42%)

1.30B(6.77%)

1.12B(6.97%)

Biosciences

1.46B(6.68%)

1.51B(7.47%)

1.51B(7.79%)

1.38B(7.31%)

1.30B(6.82%)

1.14B(7.11%)

Advanced Patient Monitoring

1.08B(4.95%)

74.00M(0.37%)

--(--)

地区

营业收入

占比

年报

年报

单季报

United States

International

Europe

Greater Asia

Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

12.79B(58.56%)

11.66B(57.80%)

11.11B(57.36%)

10.72B(56.82%)

10.37B(54.21%)

9.16B(57.00%)

9.73B(56.27%)

International

9.05B(41.44%)

8.52B(42.20%)

8.26B(42.64%)

8.15B(43.18%)

8.76B(45.79%)

6.91B(43.00%)

--(--)

Europe

--(--)

3.36B(19.43%)

Greater Asia

--(--)

2.73B(15.77%)

Other

--(--)

1.48B(8.54%)